Sudden visual loss in the untreated eye of a patient with neovascular glaucoma following an intravitreal bevacizumab injection: A case report

Xu,Ding; Hu,Liumei; Wang,Bing; Wang,Fang

doi:10.3892/ol.2013.1382

Sudden visual loss in the untreated eye of a patient with neovascular glaucoma following an intravitreal bevacizumab injection: A case report

Authors:
- Ding Xu
- Liumei Hu
- Bing Wang
- Fang Wang
View Affiliations

Affiliations: Department of Ophthalmology, Shanghai 10th People's Hospital, Tongji University School of Medicine, Shanghai 200072, P.R. China
Published online on: June 7, 2013 https://doi.org/10.3892/ol.2013.1382
Pages: 445-447

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The current study presents the case of a patient with a rare adverse event characterized by sudden vision loss in the untreated eye following an intravitreal injection of bevacizumab for neovascular glaucoma (NVG). The patient was diagnosed with NVG refractory to Ahmed glaucoma valve implantation and a vitreous hemorrhage in the right eye, which was treated with 1.25 mg intravitreal bevacizumab. Ten days after the bevacizumab injection, the left eye exhibited sudden visual loss. The patient's best‑corrected visual acuity (BCVA) decreased from 80 to 25 letters [Early Treatment Diabetic Retinopathy Study (ETDRS) chart]. A fundus examination revealed a swollen optic disk with unclear boundaries, retinal hemorrhages and thinning retinal vessels. Fundus fluorescein angiography (FA) identified hyperfluorescence in the optic disk and an enlarged foveal avascular zone. The visual field revealed quadrantal defects that confirmed the diagnosis of anterior ischemic optic neuropathy associated with ischemic maculopathy. Six months later, following medical treatment, the patient's BCVA was increased to 44 letters. However, a clinical examination found neovessels with one papilla disk (PD) above the disk. Laser photocoagulation treatment was administered immediately. The area of neovessels above the disk was reduced to 1/4 PD at the last follow-up. In conclusion, although intravitreal anti‑vascular endothelial growth factor (Bevacizumab) is an effective treatment for neovascular ocular diseases, its adverse effects must be taken into consideration for the treatment of NVG. Photocoagulation remains an effective treatment for proliferative diabetic retinopathy.

View Figures

View References

1.	Kaiser PK: Antivascular endothelial growth factor agents and their development: therapeutic implications in ocular diseases. Am J Ophthalmol. 142:660–668. 2006. View Article : Google Scholar
2.	Simó R and Hernández C: Intravitreous anti-VEGF for diabetic retinopathy: hopes and fears for a new therapeutic strategy. Diabetologia. 51:1574–1580. 2008.PubMed/NCBI
3.	Burger RA: Experience with bevacizumab in the management of epithelial ovarian cancer. J Clin Oncol. 25:2902–2908. 2007. View Article : Google Scholar : PubMed/NCBI
4.	Magdelaine-Beuzelin C, Pinault C, Paintaud G and Watier H: Therapeutic antibodies in ophthalmology: old is new again. MAbs. 2:176–180. 2010. View Article : Google Scholar : PubMed/NCBI
5.	Lambrechts D and Carmeliet P: Genetics in zebrafish, mice and humans to dissect congenital heart disease: insights in the role of VEGF. Curr Top Dev Biol. 62:189–224. 2004. View Article : Google Scholar : PubMed/NCBI
6.	Lee S, Chen TT, Barber CL, Jordan MC, Murdock J, Desai S, Ferrara N, Nagy A, Roos KP and Iruela-Arispe ML: Autocrine VEGF signaling is required for vascular homeostasis. Cell. 130:691–703. 2007. View Article : Google Scholar : PubMed/NCBI
7.	Nishijima K, Ng YS, Zhong L, et al: Vascular endothelial growth factor-A is a survival factor for retinal neurons and a critical neuroprotectant during the adaptive response to ischemic injury. Am J Pathol. 171:53–67. 2007. View Article : Google Scholar
8.	Wei W, Chen ZW, Yang Q, et al: Vasorelaxation induced by vascular endothelial growth factor in the human internal mammary artery and radial artery. Vascul Pharmacol. 46:253–259. 2007. View Article : Google Scholar : PubMed/NCBI
9.	Saint-Geniez M, Kurihara T, Sekyama E, et al: An essential role for RPE-derived solube VEGF in the maintenance of the choriocapillaris. Proc Natl Acad Sci USA. 106:18751–18756. 2009. View Article : Google Scholar : PubMed/NCBI
10.	Csaky KG, Baffi JZ, Byrnes GA, et al: Recruitment of marrow-derived endothelial cells to experimental choroidal neovascularization by local expression of vascular endothelial growth factor. Exp Eye Res. 78:1107–1116. 2004. View Article : Google Scholar
11.	Fung AE, Rosenfeld PJ and Reichel E: The International Intravitreal Bevacizumab Safety Survey: using the internet to assess drug safety worldwide. Br J Ophthalmol. 90:1344–1349. 2006. View Article : Google Scholar : PubMed/NCBI
12.	Hosseini H and Razeghinejad MR: Anterior ischemic optic neuropathy after intravitreal injection of bevacizumab. J Neuroophthalmol. 29:160–161. 2009. View Article : Google Scholar : PubMed/NCBI
13.	Battaglia Parodi M, Iacono P, Cascavilla ML, Zucchiatti I, Kontadakis DS, Vergallo S and Bandello F: Sequential anterior ischemic optic neuropathy and central retinal artery and vein occlusion after ranibizumab for diabetic macular edema. Eur J Ophthalmol. 20:1076–1078. 2010.
14.	Kim KS, Chang HR and Song S: Ischemic change after intravitreal bevacizumab (Avastin) injection for macular oedema secondary to non-ischemic central retinal vein occlusion. Acta Ophthalmol (Copenh). 86:925–927. 2008. View Article : Google Scholar : PubMed/NCBI
15.	von Hanno T, Kinge B and Fossen K: Retinal artery occlusion following intravitreal anti-VEGF therapy. Acta Ophthalmol. 88:263–266. 2010.PubMed/NCBI
16.	Bakri SJ, Snyder MR, Reid JM, Pulido JS and Singh RJ: Pharmacokinetics of intravitreal bevacizumab (Avastin). Ophthalmology. 114:855–859. 2007. View Article : Google Scholar : PubMed/NCBI
17.	Kim H, Fariss RN, Zhang C, Robinson SB, Thill M and Csaky KG: Mapping of the neonatal Fc receptor in the rodent eye. Invest Ophthalmol Vis Sci. 49:2025–2029. 2008. View Article : Google Scholar : PubMed/NCBI
18.	Aiello LP, Northrup JM, Keyt BA, Takagi H and Iwamoto MA: Hypoxic regulation of vascular endothelial growth factor in retinal cells. Arch Ophthalmol. 113:1538–1544. 1995. View Article : Google Scholar : PubMed/NCBI
19.	Blaauwgeers HG, Holtkamp GM, Rutten H, Witmer AN, Koolwijk P, Partanen TA, Alitalo K, Kroon ME, Kijstra A, van Hinsbergh VWM and Schlingermann RO: Polarized vascular endothelial growth factor secretion by human retinal pigment epithelium and localization of vascular endothelial growth factor receptors on the inner choriocapillaris. Evidence for a trophic paracrine relation Am J Pathol. 155:421–428. 1999.
20.	Sinapis CI, Routsias JG, Sinapis AI, Sinapis D, Agrogiannis G, Pantopoulou A, Theocharis SE, Baltatzis S, Patsouris E and Perrea DN: Pharmacokinetics of intravitreal bevacizumab (Avastin(R)) in rabbits. Clin Ophthalmol. 5:697–704. 2011. View Article : Google Scholar : PubMed/NCBI